Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820205 | 0.83 | CNR1 (0.40) | PKMHTR6DRD2CNR1CNR2 | |
| SCHEMBL18772814 | 0.76 | PKM (0.44) | PKMPDE10AGAAKMT2A | |
| SCHEMBL31200058 | 0.75 | SMN1; SMN2 (0.35) | PKMPDE10AGAAKMT2AMEN1 | |
| SCHEMBL31200380 | 0.74 | SMN1; SMN2 (0.40) | PKMGAAKMT2AMEN1 | |
| SCHEMBL14266781 | 0.73 | KMT2A (0.54) | DRD2GAAKMT2AFABP6 | |
| SCHEMBL31200393 | 0.71 | NPC1 (0.43) | PKMGAAKMT2AMEN1 | |
| SCHEMBL19853582 | 0.69 | HRH3 (0.46) | HRH3PKMACHEKMT2A | |
| SCHEMBL22258920 | 0.68 | MAP4K4 (0.47) | HRH3HRH4ACHEPDE10ANCF1 | |
| Methimepip SCHEMBL8320104 | 0.67 | HRH3 (0.51) | HRH3HRH4HTR6DRD2ACHE | |
| SCHEMBL10031019 | 0.66 | PKM (0.51) | PKMGAAKMT2AMEN1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507499-B2 | Substituted indole/indazole-pyrimidinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20120142696-A1 | SUBSTITUTED INDOLE/INDAZOLE-PYRIMIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142696-A1 | SUBSTITUTED INDOLE/INDAZOLE-PYRIMIDINYL COMPOUNDS | MAPK1, MAP3K1, MAP3K20 | HRH3 685/4885HRH4 936/4885PKM 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.